Primäre und sekundäre glomeruläre Erkrankungen

Schlüsselwörter

MEST-Score - Minimal Change Nephropathie - Lupusnephritis - Sjögren-Syndrom

Keywords

MEST score - minimal change nephropathy - lupus nephritis - Sjogren‘s syndrome

• Literatur

• 1 Coppo R, Peruzzi L, Amore A et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18: 1880-1888
• 2 Coppo R, Troyanov S, Bellur S et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 2014; 86: 828-836
• 3 Ding HJ, Gordon C. New biologic therapy for systemic lupus erythematosus. Curr Opin Pharmacol 2013; 13: 405-412
• 4 Freedman BI, Kopp JB, Langefeld CD et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 2010; 21: 1422-1426
• 5 Freedman BI, Langefeld CD, Andringa KK et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 2014; 66: 390-396
• 6 Furie R, Nicholls K, Cheng TT et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014; 66: 379-389
• 7 Goules AV, Tatouli IP, Moutsopoulos HM et al. Clinically significant renal involvement in primary Sjogren's syndrome: clinical presentation and outcome. Arthritis Rheum 2013; 65: 2945-2953
• 8 Iijima K, Sako M, Nozu K et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014; 384: 1273-1281
• 9 Kawamura T, Yoshimura M, Miyazaki Y et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 2014; 29: 1546-1553
• 10 Kim YC, Chin HJ, Koo HS et al. Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy. PloS one 2013; 8: e71545
• 11 Li PK, Kwan BC, Chow KM et al. Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor. Am J Med 2013; 126: 162-168
• 12 Lombel RM, Hodson EM, Gipson DS et al. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatric nephrol 2013; 28: 409-414
• 13 Lv J, Xu D, Perkovic V et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 2012; 23: 1108-1116
• 14 Pozzi C, Andrulli S, Pani A et al. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine. J Nephrol 2013; 26: 86-93
• 15 Praga M, Gutierrez E, Gonzalez E et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583
• 16 Ramos-Casals M, Brito-Zeron P, Siso-Almirall A et al. Primary Sjogren syndrome. BMJ 2012; 344: e3821
• 17 Schwartz N, Goilav B, Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol 2014; 26: 502-509
• 18 Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis rheum 2012; 64: 3660-3665
• 19 Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis rheum 2013; 65: 1586-1591
• 20 Working Group of the International Ig ANN, the Renal Pathology S. Cattran DC et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney intern 2009; 76: 534-545